Global Oncology/Cancer Drugs Market (Therapeutic Modalities, Cancer Types and Geography) - Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for<br />
treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various<br />
cancer conditions, growing popularity of advance therapies (biological <strong>and</strong> targeted drug<br />
therapies), patents expiration of leading drugs along with commercialization of biosimilars are<br />
the few factors driving the growth of global oncology drugs market. However, high cost involved<br />
in new drug development coupled with threat of failure <strong>and</strong> adverse effects associated with<br />
cancer drugs therapies would restrain the growth of the market. Commercialization of advanced<br />
therapeutics such as targeted <strong>and</strong> immunotherapies would reduce the negative influence of<br />
restraints <strong>and</strong> fuel the market growth.<br />
The global oncology drugs market is expected to reach at $111.9 billion by <strong>2020</strong>. Patent<br />
expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan <strong>and</strong> Avastin, is expected to<br />
boost the growth of cancer biosimilars market by <strong>2020</strong>. Going further, the biological therapies<br />
are expected to dominate the market by <strong>2020</strong>, due to their high efficacy, target specific action<br />
<strong>and</strong> less toxicity. Blood cancer drugs market was the largest revenue generating segment in <strong>2013</strong><br />
owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.<br />
Get Full Access for the <strong>Report</strong> at: http://www.alliedmarketresearch.com/oncology-cancer-drugsmarket<br />
Geographically, North America, dominates the market followed by Europe. North America<br />
accounted for about ~38% share in the overall oncology drugs market in <strong>2013</strong> owing to the heavy<br />
investments by multinational companies in research <strong>and</strong> development of cancer drugs,<br />
particularly immune therapeutics, favorable reimbursement policies, <strong>and</strong> high adoption rate of<br />
immunotherapies. On the other h<strong>and</strong>, Asia-Pacific market would grow at the promising CAGR of<br />
8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness<br />
towards advanced therapies namely immunotherapies <strong>and</strong> increase in per capita healthcare<br />
spending.<br />
Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation,<br />
AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. <strong>and</strong> GlaxoSmithKline. Companies<br />
operating in the cancer drugs market focus on several strategies such as collaboration, approval<br />
<strong>and</strong> acquisition.<br />
KEY BENEFITS<br />
<br />
<br />
The report provides the quantitative analysis of the current market <strong>and</strong> estimations through<br />
<strong>2013</strong>-<strong>2020</strong> that assists in identifying the prevailing market opportunities to capitalize on<br />
The report helps in underst<strong>and</strong>ing the strategies adopted by various companies for gaining<br />
market share in the cancer drugs market<br />
© ALLIED MARKET RESEARCH
Change language